Erasca, Inc.
NNASDAQ:ERASCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jonathan E. Lim
- Full Time Employees
- 103
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 3115 Merryfield Row San Diego CA United States 92121
- IPO Date
- Jul 16, 2021
- CIK
- 0001761918
- Website
- erasca.com
- Similar Companies
- Business
- Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies targeting RAS/MAPK pathway-driven cancers, which affect approximately 30% of human cancers; its pipeline includes naporafenib, a pan-RAF inhibitor for NRAS-mutant melanoma and RAS Q61X solid tumors studied in over 600 patients; ERAS-007, an oral ERK1/2 inhibitor for colorectal cancer, non-small cell lung cancer, and advanced gastrointestinal malignancies; ERAS-601, an oral SHP2 inhibitor for advanced solid tumors; ERAS-0015, a pan-RAS molecular glue evaluated in Phase 1 AURAS-1 trial for RAS-mutant solid tumors following FDA IND clearance in May 2025 and recent U.S. composition-of-matter patent issuance; ERAS-4001, a pan-KRAS inhibitor with FDA IND clearance for (K)RAS-mutant solid tumors; and ERAS-801, a CNS-penetrant EGFR inhibitor for recurrent glioblastoma multiforme, alongside a bispecific antibody targeting wildtype EGFR overexpression in head and neck squamous cell carcinoma and colorectal cancer. The company pursues three strategies: targeting upstream/downstream RAS/MAPK nodes, RAS directly, and resistance escape routes, with programs in Phase 1/2 trials including HERKULES-3 for ERAS-007 combinations, SEACRAFT-2 for naporafenib with Novartis' trametinib, and ongoing evaluations of monotherapy and combinations across multiple tumor types. Founded in 2018 and headquartered in San Diego, California, Erasca operates globally in clinical development, leveraging partnerships such as licensing agreements with Guangzhou Joyo Biotech for pan-RAS inhibitors, Medshine for pan-KRAS inhibitors, NiKang Therapeutics, Asana BioSciences, and Katmai Pharmaceuticals; recent developments encompass FDA IND approvals for ERAS-0015 and ERAS-4001 in 2025, preclinical data presentations at the AACR Annual Meeting in April 2025 highlighting superior potency, Q3 2025 business updates advancing the RAS franchise toward 2026 Phase 1 data readouts, and a cash position funding operations into late 2028.
Company News
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
Erasca to Present at Upcoming Conferences in November
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Erasca, Inc. - ERAS
ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
Erasca (NASDAQ:ERAS) Shares Down 5.8% – What’s Next?
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
Erasca, Inc. (NASDAQ:ERAS) Stock Has Consensus Target Price of $22.09
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims
Engineers Gate Manager LP Takes Position in Erasca, Inc. $ERAS
Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium